Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10637/10229
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.other | UCH. Departamento de Cirugía (Extinguido) | - |
dc.contributor.other | UCH. Departamento de Farmacia | - |
dc.contributor.other | Producción Científica UCH 2018 | - |
dc.contributor.other | UCH. Departamento de Medicina y Cirugía | - |
dc.creator | Muedra Navarro, Vicente | es |
dc.creator | Moreno Royo, Lucrecia | es |
dc.creator | Rodilla Alama, Vicente | es |
dc.creator | Arce Recatalá, Cristina | es |
dc.creator | Montó Guillot, Fermí | es |
dc.creator | Blázquez Bernal, Águeda | es |
dc.creator | Pérez Sánchez, Paloma | es |
dc.creator | D'Ocon Navaza, Pilar | es |
dc.date | 2018 | es |
dc.date.accessioned | 2019-05-11T04:00:51Z | - |
dc.date.available | 2019-05-11T04:00:51Z | - |
dc.date.issued | 2018-09-01 | - |
dc.identifier.citation | Muedra, V., Moreno, L., Rodilla, V., Arce, C., Montó, F., Blázquez, Á. et al. (2018). Dexamethasone preconditioning in cardiac procedures reduces decreased antithrombin activity and is associated to beneficial outcomes : role of endothelium. Frontiers in Pharmacology, vol. 9 (septembre), art. 1014. DOI: https://doi.org/10.3389/fphar.2018.01014 | - |
dc.identifier.issn | 1663-9812. | - |
dc.identifier.uri | http://hdl.handle.net/10637/10229 | - |
dc.description | Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.frontiersin.org/articles/10.3389/fphar.2018.01014/full | es |
dc.description.abstract | Introduction: Decreased antithrombin (AT) activity in patients scheduled for cardiovascular surgery under cardiopulmonary bypass (CPB) is related to increased postoperative complications and hospitalization time. Indirect evidence suggests that glucocorticoids mitigate this decreased AT activity. To better understand the beneficial effects of AT we have analyzed: (i) the clinical relevance of acute dexamethasone (DX) administration before cardiac surgery on AT activity, (ii) the modulation by DX of AT expression in human endothelial cells (hECs), (iii) the activity of AT on migration and angiogenesis of hECs, or on angiogenesis of rat aorta. Methods: A retrospective cohort study in patients undergoing aortic valve replacement surgery was designed to evaluate the effect of DX administration on AT activity at five separate time points: preoperatively, during CPB, at intensive care unit admission and at 12 and 24 h post-intervention. We have analyzed also clinical differences in postoperative outcomes as safety and the length of stay in hospitalization. Changes in mRNA levels of AT induced by DX were determined by qRT-PCR in human coronary (hCEC), aorta (hAEC) and cardiac microvasculature (hCMEC) endothelial cells. AT activity on migration and angiogenesis were also assayed. Angiogenic growth of rat aortic rings incubated in Matrigel R was determined in presence and absence of AT. Results: The cohort comprised 51 patients in the control group and 29 patients in the group receiving dexamethasone. Preoperative DX supplementation reduced intraoperative decrease of AT activity (67.71 10.49% DX treated vs. 58.12 9.11% untreated, p < 0.001) that could be related to a decrease in the hospitalization time (7.59 4.08 days DX treated vs. 13.59 16.00 days untreated, p = 0.014). Treatment of hECs with 500 nM DX slightly increased AT expression. Incubation with 0.5 and 1 IU/mL of AT increased migration and angiogenesis in hCAECs and hAECs, but not in hCMECs. The same concentrations of AT potentiated angiogenic sprouting of new vessels from rat aorta. Conclusion: Preoperative DX supplementation could be an interesting procedure to avoid excessive decrease in AT levels during cardiac surgery. Positive outcomes associated with maintaining adequate AT levels could be related to its potential beneficial effect on endothelial function (migration and angiogenesis). | - |
dc.format | application/pdf | es |
dc.language.iso | en | es |
dc.publisher | Frontiers Media. | - |
dc.relation | Este artículo (UGP-15-171) fue subvencionado por la Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO) de la Comunitat Valenciana y por la Conselleria de Sanitat de la Generalitat Valenciana. | - |
dc.relation | UCH. Financiación Autonómica. | - |
dc.relation.ispartof | Frontiers in Pharmacology, vol. 9 (septiembre 2018), art. 1014. | - |
dc.rights | http://creativecommons.org/licenses/by/4.0/deed.es | es |
dc.subject | Heart - Surgery. | es |
dc.subject | Endothelium. | es |
dc.subject | Dexamethasone - Therapeutic use. | es |
dc.subject | Endotelio. | es |
dc.subject | Antithrombins. | es |
dc.subject | Dexametasona - Uso terapéutico. | es |
dc.subject | Corazón - Cirugía. | es |
dc.subject | Antitrombinas. | es |
dc.title | Dexamethasone preconditioning in cardiac procedures reduces decreased antithrombin activity and is associated to beneficial outcomes : role of endothelium | es |
dc.type | Artículo | es |
europeana.dataProvider | UNIVERSIDAD SAN PABLO CEU | - |
europeana.isShownAt | http://hdl.handle.net/10637/10229 | - |
europeana.object | http://repositorioinstitucional.ceu.es/visor/libros/709542/thumb_europeana/709542.jpg | - |
europeana.provider | Hispana | - |
europeana.rights | http://creativecommons.org/publicdomain/zero/1.0/ | - |
europeana.type | TEXT | - |
dc.identifier.doi | https://doi.org/10.3389/fphar.2018.01014 | - |
dc.relation.projectID | UGP-15-171 | - |
dc.centro | Universidad Cardenal Herrera-CEU | - |
Aparece en las colecciones: | Dpto. Farmacia |
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.